• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Maternal Health Inequities: Improving Access to Postpartum Depression Treatment

Commentary
Podcast

Douglas Weber, MD, explains how zuranolone has changed the landscape for postpartum depression treatment, addressing a gap in care within maternal health.

Zuranolone (Zurzuvae; Sage Therapeutics/Biogen), the first oral medication approved by the FDA for postpartum depression (PPD), became available at the end of last year, offering physicians and patients an effective and more convenient treatment option for managing PPD.

In this episode of Managed Care Cast, hosted by the Center on Health Equity & Access, Douglas Weber, MD, OB-GYN at MomDoc, explained why this therapy has impacted maternal and postpartum care. Previously, treatment for PPD was limited to intravenous (IV) administration of brexanolone (Zulresso) or commonly prescribed antidepressant medications which are not necessarily designed to address the hormonal components of PPD.

iTunes
TuneIn
Stitcher
Spotify

Related Videos
Debra Patt, MD, PhD, MBA, MPH
Carrie Kozlowski, OT, MBA, Upfront Healthcare
Debra Patt, MD, PhD, MBA, MPH
Sarah Anderson, oncology strategy lead director, Novotech
Gladys Antelo-Allen
Robin Glasco, Spencer Stuart
Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson chair in preventative cardiology, Tulane University School of Medicine
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.